Feature

Human-Relevant Discovery: iPSC Models and the Future of Rare Disease R&D

A Q&A with iXCells Biotechnologies CEO, Steve Smith

  • By

  • February 25, 2026

  • 9 min

Share

iPSC-derived models are revolutionizing early drug development for rare diseases by offering patient-specific insights that allow researchers to engage with human biology earlier in the process. These models facilitate improved target validation and decision-making by providing more accurate reflections of disease mechanisms compared to traditional cellular models. The drive towards standardized, integrated workflows is vital for generating reliable data across various systems, ultimately expediting the transition from research to effective therapies.

Original Source(s)

Human-Relevant Discovery: iPSC Models and the Future of Rare Disease R&D

A Q&A with iXCells Biotechnologies CEO, Steve Smith

  • February 25, 2026

  • 9 min

Related Content

Refining Single-Cell Metabolomics with Ion Mobility

Ion mobility-resolved mass cytometry expands metabolite coverage across thousands of single cells 

  • February 24, 2026

  • 2 min
Tracing Metabolic Inflexibility in Fanconi Anemia 

Stable-isotope glucose tracing reveals impaired fuel switching and altered energy use in a rare DNA-repair disorder 

FDA Approves First Once-Daily Oral Therapy for Acromegaly

Once-daily paltusotine offers an oral alternative to monthly injections for eligible adults.